Shares of Bio-Techne Co. (NASDAQ:TECH – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the ...

Bio-Techne Corp. closed 7.97% below its 52-week high of $85.57, which the company reached on May 15th.

ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that ...

Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, ...

Citigroup has recently reduced BIO-TECHNE Corp (TECH) stock to Neutral rating, as announced on May 22, 2024, according to Finviz. Earlier, on February 8, 2024, Scotiabank had initiated the stock to ...

Through its Protein Sciences business segment, Bio-Techne is one of the world's leading suppliers of proteins, such as cytokines and growth factors, immunoassays, antibodies, and reagents to the ...

Highlights from the first day included updates from several firms about their China businesses and M&A strategies.

Bio-Techne Corporation ( NASDAQ:TECH ) saw a double-digit share price rise of over 10% in the past couple of months ...

Bio-Techne Corp. closed $10.84 below its 52-week high ($85.57), which the company achieved on May 15th.

In a report released on January 10, Conor McNamara from RBC Capital maintained a Hold rating on Bio-Techne (TECH – Research Report), with a ...

The global Spatial Genomics & Transcriptomics market is expected to grow to USD 995.7 Million by 2029, up from USD 554.5 ...

These products are not directly competing with other spatial platform technologies. Bio-Techne is well-known for its RNAscope ...